Alnylam Pharmaceuticals Inc (ALNY)vsFilana Therapeutics, Inc. (FLNA)
ALNY
Alnylam Pharmaceuticals Inc
$301.19
-0.30%
HEALTHCARE · Cap: $40.19B
FLNA
Filana Therapeutics, Inc.
$1.44
-7.69%
HEALTHCARE · Cap: $77.78M
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 8.4% profit margin vs 0.0%. ALNY appears more attractively valued with a PEG of 0.60. ALNY earns a higher WallStSmart Score of 59/100 (C).
ALNY
Buy59
out of 100
Grade: C
FLNA
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+84.8%
Fair Value
$2113.13
Current Price
$301.19
$1811.94 discount
Intrinsic value data unavailable for FLNA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 50.5x book value
Expensive relative to growth rate
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth, PEG Ratio. Revenue growth of 84.9% demonstrates continued momentum. PEG of 0.60 suggests the stock is reasonably priced for its growth.
Bull Case : FLNA
The strongest argument for FLNA centers on Price/Book.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 129.8x leaves little room for execution misses.
Bear Case : FLNA
The primary concerns for FLNA are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while FLNA is a value play — different risk/reward profiles.
ALNY carries more volatility with a beta of 0.38 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (59/100 vs 36/100) and 84.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Filana Therapeutics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
FuelNation Inc., a development stage company, engages in the purchase, transportation, storage, and resale of petroleum products. The company is headquartered in West Palm Beach, Florida.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?